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Background: Administration of recombinant G-CSF following cytoreductive therapy enhances the recovery of
myeloid cells, minimizing the risk of opportunistic infection. Free G-CSF, however, is expensive, exhibits a short
half-life, and has poor biological activity in vivo.
Methods: We evaluated whether the biological activity of G-CSF could be improved by pre-association with anti-G-CSF
mAb prior to injection into mice.
Results: We find that the efficacy of G-CSF therapy can be enhanced more than 100-fold by pre-association of G-CSF
with an anti-G-CSF monoclonal antibody (mAb). Compared with G-CSF alone, administration of G-CSF/anti-G-CSF mAb
complexes induced the potent expansion of CD11b+Gr-1+ myeloid cells in mice with or without concomitant
cytoreductive treatment including radiation or chemotherapy. Despite driving the dramatic expansion of myeloid
cells, in vivo antigen-specific CD8+ T cell immune responses were not compromised. Furthermore, injection of
G-CSF/anti-G-CSF mAb complexes heightened protective immunity to bacterial infection. As a measure of clinical
value, we also found that antibody complexes improved G-CSF biological activity much more significantly than
pegylation.
Conclusions: Our findings provide the first evidence that antibody cytokine complexes can effectively expand
myeloid cells, and furthermore, that G-CSF/anti-G-CSF mAb complexes may provide an improved method for the
administration of recombinant G-CSF.
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Protein therapeuticsBackground
The advent of recombinant G-CSF and related factors
able to induce myeloid cell expansion have rapidly revo-
lutionized the treatment of cancer and other diseases
[1-5]. First cloned in 1986, G-CSF was FDA approved
five years later as an adjuvant to overcome neutropenia,
the dose-limiting toxicity of many cancer regimens.* Correspondence: markrubinstein@musc.edu
1Department of Biological Sciences, The University of California, San Diego,
La Jolla, CA 92093, USA
2Department of Surgery, Medical University of South Carolina, Charleston, SC
29403, USA
Full list of author information is available at the end of the article
© 2013 Rubinstein et al.; licensee BioMed Cen
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumConsistent with its clinical use [6], administration of G-
CSF induces multiple biological effects in mice, most
notably, the expansion and activation of neutrophils and
their progenitors [7-13]. It is the accelerated recovery of
these cells that is thought to help reduce the risk of in-
fection and other complications during many forms of
cancer treatment. More recently, it was found that ad-
ministration of G-CSF can also facilitate mobilization of
hematopoietic progenitor cells to the peripheral blood.
These mobilized progenitor cells are not only more eas-
ily accessible clinically than traditional bone marrow
donor cells but more effective at inducing myeloid celltral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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tients [14,15]. Currently there are multiple indications
for the administration of G-CSF including both the in-
duction of myeloid cell recovery during iatrogenic or
disease-related myelosuppression and the mobilization
of progenitor cells in individuals donating peripheral
blood stem cells for transplantation. G-CSF-related
drugs represent one of the most important and widely
used protein therapeutics in patients.
Despite the potency of G-CSF therapy, there are signifi-
cant clinical limitations. Foremost, the half-life of recom-
binant G-CSF is relatively short (3.5 hours) [2,16]. This
rapid loss of G-CSF in vivo means that the biological activ-
ity of administered G-CSF is transient and patients must
receive repeated dosing to achieve a durable myeloid cell
recovery. As a means of prolonging the half-life of G-CSF
and improving its biological activity in vivo, it was found
that, as with other cytokines [17,18], pegylation of G-CSF
resulted in improved pharmokinectics and enhanced bio-
logical activity [2,19]. Thus, pegylated G-CSF has a half-
life estimated at over 15 hours [16,20]. This effect is likely
due to diminished renal clearance, as bilateral nephrec-
tomy of rats decreases the clearance of free G-CSF but not
pegylated G-CSF [21]. Because pegylated G-CSF can be
safely administered with reduced dosing requirements, it
was FDA-approved in 2002 [2], and it is now becoming
the drug of choice where G-CSF is indicated. Despite these
advances, there remain significant limitations with
pegylated G-CSF [22-28]. It is difficult to manufacture and
costly to administer large amounts of biologically active
cytokine, and pegylation per se is known to reduce the
in vitro activity of many cytokines. Furthermore, recent
findings suggest the existence of anti-PEG (polyethylene
glycol) antibodies in up to 25% of healthy individuals
[27-29]. While the clinical significance of such antibodies
in the administration of pegylated G-CSF is not known,
anti-PEG antibodies have been documented to neutralize
the activity PEG-uricase and PEG-asparaginase in human
patients [25-27], and could provide an explanation for pa-
tients who fail to effectively respond to the administration
of other pegylated protein therapeutics.
An alternative method for increasing the biological ac-
tivity of a cytokine in vivo is pre-association with a
cytokine-specific monoclonal antibody or a soluble recep-
tor prior to injection. Thus, pre-association of IL-2, IL-3,
IL-4, IL-6, IL-7, IFNα, or TNFα with specific cytokine-
specific monoclonal antibodies dramatically improves bio-
logical activity in vivo [30-32]. Similarly, pre-association
with soluble receptors can greatly improve the biological
activity of IL-4, IL-6, and IFNα [32,33]. While these find-
ings demonstrated that cytokine complexes could induce
the activation and expansion of multiple cell types includ-
ing B cells and mast cells, we and others have found that
cytokine complexes, including with IL-15, could also beused to facilitate the expansion of T cells and natural killer
cells [34-39].
Although cytokine complexes can effectively drive the
expansion and activation of a wide range of cell popula-
tions in vivo, it is not clear whether cytokine complexes
can universally act on all types of potential target cells
[31]. The localization of cytokine complexes in vivo
might favor their activity on some cell populations but
not others. Alternatively, some cytokines may be inher-
ently more amenable to enhanced activity when admin-
istered as a cytokine complex due to the mechanism by
which they induce receptor signaling. Finally, it is pos-
sible that accessory cells necessary to facilitate the mech-
anism by which cytokine complexes act are not present
after cytoreductive therapy. The latter would represent
an obstacle limiting the use of cytokine complexes in
many types of cancer therapy. Our purpose was to ad-
dress these issues by the evaluation of cytokine-antibody
complexes composed of G-CSF and anti-G-CSF mAb.
Upon association, we find that these cytokine complexes
are potent stimulators of neutrophils, a G-CSF-respon-
sive cell type not previously shown to be responsive to
cytokine complexes. Furthermore, our data demonstrate
that these G-CSF/anti-G-CSF mAb complexes facilitate
myeloid cell recovery after cytoreductive therapy without
inducing a suppressive environment that compromises
antigen-specific CD8+ T cell responses. These findings
suggest a novel strategy for enhancing the clinical utility
of recombinant G-CSF.
Results
Pre-association of G-CSF with anti-G-CSF mAb leads to
greatly enhanced biological activity
To test the efficacy of G-CSF/anti-G-CSF mAb complexes,
B6 mice were injected i.p. once with complexes containing
0.5 μg G-CSF pre-associated with 2.5 μg anti-G-CSF mAb
(clone BVD11-37G10). We observed that G-CSF/anti-G-
CSF mAb complexes induced a marked increase in the per-
cent of splenic CD11b+Gr-1+ myeloid cells (Figure 1A).
This effect was more dramatic after three injections of G-
CSF/anti-G-CSF mAb complexes (1.5 μg G-CSF and 7.5 μg
anti-G-CSF mAb) over 1 week, which induced over a 20-
fold increase in the number of CD11b+Gr-1+ myeloid cells
per spleen (Figure 1B). Importantly, administration of cyto-
kine or antibody alone did not significantly alter the num-
ber of CD11b+Gr-1+ myeloid cells. In addition to spleen,
we observed increased frequencies of CD11b+Gr-1+ mye-
loid cells in the blood, bone marrow, lung, but not the
lymph node (Additional file 1: Figure S1). The phenotype
of these expanded myeloid cells is consistent with that of
neutrophils (or neutrophilic granulocytes), a cell population
known to be G-CSF responsive [1,40,41]. As previously ob-
served, these myeloid cells exhibited a higher FSC/SSC pro-
file indicating a larger and more granular cell morphology






































































































Figure 1 G-CSF/anti-G-CSF mAb complexes exhibit enhanced
biological activity in comparison with G-CSF. (A) B6 mice were
injected i.p. once with G-CSF/anti-G-CSF mAb complexes (0.5 μg G-CSF
plus 2.5 μg anti-G-CSF mAb), cytokine alone (0.5 μg G-CSF), antibody
alone (2.5 μg anti-G-CSF mAb), or vehicle alone. CD11b+Gr-1+ myeloid
cells were identified by FACS analysis of spleens cells at 48 hours. (B) B6
mice were injected i.p. three times (on days 1, 3, and 5) with G-CSF/
anti-G-CSF mAb complexes (1.5 μg G-CSF plus 7.5 μg anti-G-CSF mAb)
or controls. Spleens were harvested on day 7. Shown are the number of
CD11b+Gr-1+ myeloid cells identified by FACS. Each triangle represents
an individual mouse and the bar indicates the mean. *P-values ≤ 0.05
were generated by Wilcoxon Rank-Sum test. (C) B6 mice were injected
once with G-CSF only (1.5 μg) or with G-CSF/anti-G-CSF mAb complexes
(1.5 μg G-CSF plus 7.5 μg anti-G-CSF mAb). For the 1/10 condition, mice
were injected with 0.15 μg G-CSF plus 0.75 μg anti-G-CSF mAb, and for
the 1/100 condition, an additional 10-fold dose reduction. The percent
of CD11b+Gr-1+ myeloid cells in the spleen was determined by FACS
analysis at 36 hours. Each triangle represents an individual mouse and
the bar indicates the mean. *P-values ≤ 0.05 were generated by
Wilcoxon Rank-Sum test. (D) B6 mice (n = 4/group) were injected once
i.p. with G-CSF/anti-G-CSF mAb complexes (1.5 μg G-CSF plus 7.5 μg
anti-G-CSF mAb), cytokine alone (1.5 μg G-CSF), pegylated G-CSF (3.1 μg
PEG-G-CSF), or vehicle alone. Peripheral blood was harvested prior to
injection and on days 1, 2, 4, and 6. The percentage of CD11b+Gr-1+
myeloid cells was determined by FACS analysis. The error bars indicate
standard deviation. *P-values < 0.01 were generated by a repeated
measures design with group-time interactions tested at each timepoint.
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the two commonly described CD11b+Gr-1+ subpopulations
[43,44], the G-CSF/anti-G-CSF mAb complex-expanded
population was Ly6G+Ly6Clow and not Ly6G-Ly6Chi
(Additional file 1: Figure S2). Titration of G-CSF/anti-G-
CSF mAb complexes versus G-CSF alone revealed that
0.015 μg of G-CSF complexed with anti-G-CSF mAb was
more biologically active than 1.5 μg of G-CSF alone, in-
dicating a ~100-fold increase in biological activity upon as-
sociation of G-CSF with anti-G-CSF mAb (Figure 1C).
Furthermore, enhanced frequencies of myeloid cells
persisted for 4 days after administration of the cytokine
complex before declining (Figure 1D). In contrast, the ad-
ministration of an equal molar dose of either free G-CSF
or pegylated G-CSF led to markedly lower responses, with
elevated myeloid cells persisting for only one day with free
G-CSF and for 2 days with pegylated G-CSF. We also ob-
served that pre-association of anti-G-CSF mAb could dir-
ectly enhance the biological activity of pegylated G-CSF as
measured by increased numbers of myeloid cells in the
spleen following a single injection of pegylated cytokine
and/or antibody (Additional file 1: Figure S3).
While G-CSF/anti-G-CSF mAb complexes induced
the potent expansion of CD11b+Gr-1+ myeloid cells, it
was important to assess whether other cell populations
were affected. To maximize any changes observed upon
administration of cytokine complexes, we treated mice
with G-CSF/anti-G-CSF mAb complexes every 48 hours
for 20 days. We observed no significant differences in

























Figure 2 G-CSF/anti-G-CSF mAb complexes enhance immunity
against bacterial infection. (A) B6 mice (n = 5/group) were treated
i.p. on days 1, 3, and 5 with G-CSF/anti-G-CSF mAb complexes
(1.5 μg G-CSF plus 7.5 μg anti-G-CSF mAb), G-CSF alone (1.5 μg
G-CSF), or vehicle alone. On day 7, mice were injected i.v. with 1x105
colony-forming units (CFU) of Listeria monocytogenes (LM-OVA).
(B) On day 10, spleens were harvested and the number of CFU was
determined. The triangles indicate individual mice and the bar
indicates the average per group. *P-values ≤ 0.05 were generated by
Wilcoxon Rank-Sum test.
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(CD8+ or CD4+), or dendritic cells (CD11c+) among
lymphocyte-gated cells (Additional file 1: Figure S4).
Again, CD11b+Gr-1+ myeloid cells were expanded sys-
temically in spleen, peripheral blood, and bone marrow
(Additional file 1: Figure S4B & C). Also, as expected
based on studies with G-CSF alone [8,9], in mice treated
every 48 hours for 1 week with G-CSF/anti-G-CSF mAb
complexes, we observed increases in hematopoietic pro-
genitor cells in the spleen and peripheral blood identi-
fied as lineage negative and expressing Sca1 and c-Kit
(Additional file 1: Figure S5). It is also relevant that we
did not observe significant changes in hematocrit levels
(Additional file 1: Figure S6), suggesting a lack of toxicity
consistent with previous observations using G-CSF
transgenic mice [45].
To verify the specificity of G-CSF/anti-G-CSF mAb com-
plexes for CD11b+Gr-1+ myeloid cells and to assess whether
these complexes induced proliferation of other cell popula-
tions, we treated mice with BrdU during administration of
cytokine complexes or controls. We observed an enhanced
percentage of BrdU+ CD11b+Gr-1+ myeloid cells but not
other cell populations in mice treated with G-CSF/anti-G-
CSF mAb complexes (Additional file 1: Figure S7). G-CSF
administration alone had no effect. As an additional con-
trol, injection of mice with IL-15/sIL-15Rα-Fc cytokine
complexes [35-37] induced proliferation of CD8+ T cells
but not myeloid cells. Cumulatively, these results suggest
that G-CSF/anti-GCSF mAb complexes act directly to spe-
cifically induce proliferation of CD11b+Gr-1+ myeloid cells
or their precursors. However, we cannot formally exclude
the possibility that G-CSF/anti-GCSF mAb complexes in-
duce the localization of dividing cells into the periphery [46].
To determine if the phenotypic changes induced by
administration of G-CSF/anti-G-CSF mAb complexes
were functionally relevant, we assessed whether adminis-
tration of cytokine complexes would lead to heightened
protective immunity against Listeria monocytogenes.
In contrast to mice injected with free G-CSF alone
(a subtherapeutic dose) or vehicle alone, mice injected
with G-CSF/anti-G-CSF mAb complexes demonstrated
a roughly 100-fold reduction in bacterial counts within
the spleen at day 3 post-infection (Figure 2).
No evidence of G-CSF-mediated suppression of CD8+ T
cell immune responses
It is becoming increasingly well recognized that effective
cancer therapy often requires the expansion and survival
of CD8+ tumor-specific T cell response [47]. While expan-
sion of myeloid cells during cytoreductive therapy in can-
cer patients is important for immunity to infection, in
some settings, certain myeloid cell subpopulations have
immunosuppressive activity [48,49]. Thus, an important
question is whether the dramatic increase in CD11b+Gr-1+myeloid cells or other biological changes following admin-
istration of a high dose of G-CSF might suppress CD8+
T cell responses [50,51]. To assess this possibility, we eval-
uated the response of antigen-specific OT-I donor T cells
following infection with vesicular stomatitis virus genetic-
ally engineered to express ovalbumin (VSV-OVA). In this
model, the OVA-specific donor CD8+ T cells undergo an
expansion, a contraction, and a memory phase following
infection (Figure 3A) [39]. We found that administration
of G-CSF/anti-G-CSF mAb complexes during the first
three days of infection did not alter the kinetics of the
CD8+ T cell response (Figure 3B), despite a nearly 3-fold
increase in the percentage of CD11b+Gr-1+ myeloid cells
in the peripheral blood (Figure 3C, D). As VSV-OVA rep-
resents an extremely potent method for activating naïve
OT-I T cells, we also assessed the impact of CD11b+Gr-1+
myeloid cell expansion on antigen-specific OT-I CD8+
T cell responses after stimulation with OVAp and poly I:C,
a less effective method of inducing T cell expansion
(Figure 3E). Similarly, administration of G-CSF/anti-G-
CSF mAb complexes did not affect the expansion of OT-I
CD8+ T cells induced by OVAp and poly I:C vaccination
despite the dramatic accumulation of CD11b+Gr-1+ mye-































































































































































Figure 3 CD8+ T cell responses are normal in the context of G-CSF/anti-G-CSF mAb-mediated expansion of CD11b+Gr-1+ myeloid cells.
(A) OT-I CD8+ T cells (105) were transferred to B6 mice and infected with VSV-OVA one day later. On day 1, day 2, and day 3 post-infection, mice
were treated i.p. with G-CSF/anti-G-CSF mAb complexes (1 μg G-CSF plus 5 μg anti-G-CSF mAb), G-CSF alone (1 μg G-CSF), or vehicle alone
(n = 4/group). (B) Peripheral blood was harvested at the timepoints indicated and the percentage of donor OT-I CD8+ T cells among lymphocytes
was assessed. (C) As in ‘B’ except the percentage of myeloid cells (CD11b+Gr-1+) among peripheral blood cells was assessed. (D) Representative
data from ‘C’ on day 4. (E) OT-I CD8+ T cells (106) were transferred to B6 mice on day −1. On day 0, day 1, and day 2, mice were injected i.p. with
G-CSF/anti-G-CSF complexes (1.5 μg G-CSF plus 7.5 μg anti-G-CSF mAb). On day 1, mice also received 50 μg of OVA peptide i.v. followed shortly
afterwards with one injection i.p. of poly I:C (n = 2-3/group). (F) Peripheral blood was harvested at the time-points indicated and the percentage
of donor OT-I CD8+ T cells among lymphocytes was assessed. (G) As in ‘F’ except the percentage of myeloid cells (CD11b+Gr-1+) among
peripheral blood cells was assessed. (H) Representative data from ‘G’ on day 3. The error bars in ‘B’, ‘C’, ‘F’, and ‘G’, indicate standard deviation.
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treated mice did not suppress IL-2-induce proliferation of
activated CD8+ T cells (Additional file 1: Figure S8).
G-CSF/anti-G-CSF mAb complexes enhance CD11b+Gr-1+
myeloid cell recovery after cytoreductive therapy
As the mechanism of action for antibody cytokine
complexes is not precisely known, it is possible thatcytoreductive therapies might ablate host cells mechanistic-
ally important in the improved biological activity exhibited
by cytokine complexes. We tested this possibility in mice
after sublethal irradiation or cyclophosphamide administra-
tion. In both cases, administration of G-CSF/anti-G-CSF
mAb cytokine complexes, but not G-CSF alone, induced
the potent expansion of CD11b+Gr-1+ myeloid cells

























0 1 2 3 4 5 (days)6 7
B

























































0 2 4 6 8 10 (days)12
Figure 4 G-CSF/anti-G-CSF mAb complexes expand CD11b+Gr-1+ myeloid cells after cytoreductive therapy. (A) B6 mice were sublethally
irradiated (600 rad) on day 0 and treated i.p. on day 1, day 3, and day 5 with G-CSF/anti-G-CSF mAb complexes (1 μg G-CSF plus 5 μg anti-G-CSF
mAb), G-CSF alone (1 μg G-CSF), vehicle alone, or IL-15/sIL-15Rα complexes (1.5 μg mIL-15 plus 7 μg sIL-15Rα-Fc) (n = 2/group). (B) Spleen cells were
harvested on day 7 and analyzed by FACS analysis, and the absolute number of cells was determined. (C) Flow cytometric data from ‘B’. CD11b and
Gr-1 staining (top row) was gated with a large FSS/SSC gate, while CD8 and CD4 staining (bottom row) was gated with a tight lymphocyte gate. (D)
B6 mice were treated with cyclophosphamide (4 mg) on day 0 and treated i.p. on day 1, day 3, and day 5 with G-CSF/anti-G-CSF mAb complexes
(1 μg G-CSF plus 5 μg anti-G-CSF mAb), G-CSF alone (1 μg G-CSF), or vehicle alone (n = 4/group). (E) The percentage of CD11b+Gr-1+ within the
peripheral blood. All data are representative of 2 independent experiments.
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ation induced the expansion of CD8+ T cells but not
CD11b+Gr-1+ myeloid cells. Cumulatively, these results
demonstrate that cytoreductive therapy does not result
in the destruction of cells essential to the enhanced ac-
tivity of G-CSF/anti-G-CSF mAb complexes.
In addition to promoting myeloid recovery during
standard cytoreductive therapy, G-CSF also facilitates
myeloid recovery after bone marrow transplantation in
human patients [52]. To assess whether G-CSF/anti-GCSF mAb complexes could also facilitate the recovery
of myeloid cells during bone marrow transplantation, we
reconstituted lethally irradiated CD45.1 mice with B6
bone marrow. Mice were then treated every 48 hours
with G-CSF/anti-GCSF mAb complexes, G-CSF alone,
or vehicle alone, for one or three weeks. We observed
striking CD11b+Gr-1+ myeloid cell recovery at both the
one and three week time-points (Additional file 1: Figure
S9A & B). These expanded myeloid cells represented
both host and donor cells (Additional file 1: Figure S9B),



















































Figure 5 G-CSF/anti-G-CSF mAb-mediated expansion of CD11b+Gr-1+
myeloid cells during myelosuppression does not impair
antigen-specific CD8+ T cell proliferative responses. (A) B6 mice
(n = 4/group) were treated with 4 mg cyclophosphamide (CTX) on
day −1 and adoptively transferred with 106 pmel-1 CD8+ T cells on
day 0. On days 1 and 10, mice received a prime boost vaccination s.
c. with gp10025-33 peptide (100 μg, i.v.) concomitant with poly I:C
(200 μg, i.p.). On day 0, day 2, and day 4, mice were treated i.p. with
G-CSF/anti-G-CSF mAb complexes (1 μg G-CSF plus 5 μg anti-G-CSF
mAb), G-CSF alone (1 μg G-CSF), or vehicle alone (n = 4/group).
(B) Peripheral blood was harvested at the timepoints indicated and
the percentage of donor pmel-1 CD8+ T cells among lymphocytes
was assessed by flow cytometry. (C) The percentage of myeloid
cells (CD11b+Gr-1+) among peripheral blood was assessed at day 9.
All data are representative of 2 independent experiments.
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exhibited broad activity. Notably, at three weeks following
bone marrow transplantation, spleens were significantly
enlarged in mice treated with G-CSF/anti-G-CSF mAb
complexes versus G-CSF alone or vehicle alone (Add-
itional file 1: Figure S9C). This increase in spleen size was
largely attributable to increased numbers of CD11b+Gr-1+
myeloid cells (Additional file 1: Figure S9D).
While G-CSF/anti-G-CSF mAb complexes enhanced
myeloid cell recovery, these complexes failed to facilitate
the recovery of the lymphoid cells such as CD8+ T cells
(Figure 4, Additional file 1: Figures S4, & S7). Thus, we
asked whether we might see a more complete hemato-
poeitic recovery during bone marrow transplantation by
combining G-CSF/anti-GCSF mAb complexes with an
agent capable of driving CD8+ T cell recovery, such
as IL-15/sIL-15Rα-Fc complexes. Consistent with this
hypothesis, after bone marrow transplantation, we ob-
served the recovery of both myeloid and lymphoid cell
populations only after treatment with both G-CSF/anti-
G-CSF mAb complexes and IL-15/sIL-15Rα-Fc com-
plexes (Additional file 1: Figure S10).
Enhanced recovery of CD11b+Gr-1+ myeloid cells
following administration of G-CSF/anti-G-CSF mAb
complexes does not impair antigen-specific CD8+ T cell
responses during myelosuppression
Although we established that elevated frequencies of
CD11b+Gr-1+ myeloid cells did not inhibit CD8+ T cell re-
sponses in normal mice, it was important to assess these
parameters during cytopenic conditions which could
theoretically favor the G-CSF-mediated development of
suppressive myeloid cells. Thus, we utilized an antigen-
specific vaccination model that we have shown induces
effective anti-tumor CD8+ T cell immunity in the context
of cyclophosphamide (CTX)-induced immunosuppresions
[53]. Mice were treated with CTX, adoptively transferred
with naïve pmel-1 CD8+ T cells, and then given a prime/
boost vaccination with the gp10025-33 peptide/poly I:C
as outlined in Figure 5A. Mice were treated with G-
CSF/anti-G-CSF mAb complexes for 5 days after CTX
treatment and during the priming phase. As shown in
Figure 5B, independent of administration of G-CSF/anti-
G-CSF mAb complexes, the prime/boost vaccination in-
duced a vigorous expansion of pmel-1 CD8+ T cells. The
effectiveness of the G-CSF/anti-G-CSF mAb complexes
was apparent from the potent expansion of CD11b+Gr-1+
myeloid cells observed in the peripheral blood at day 9 fol-
lowing CTX treatment (Figure 5C). These results demon-
strate that even in the context of cytoreductive therapy as
may occur during cancer therapy, the increased numbers
and percentages of CD11b+Gr-1+ myeloid cells in the per-
iphery did not inhibit the expansion of antigen-specific
CD8+ T cells.Discussion
While the administration of G-CSF-related drugs pro-
vides a highly effective strategy for maintaining innate im-
munity in the context of cytoreductive cancer therapies,
these drugs are expensive and exhibit limited biological
activity. In this study, we find that the biological activity
of G-CSF can be dramatically enhanced, even more so
than with pegylation, by pre-association with an anti-
G-CSF mAb (Figure 1). Administration of G-CSF/anti-G-
CSF mAb complexes specifically drove the expansion of
CD11b+Gr-1+ myeloid cells without affecting other major
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consistent with neutrophils, a cell population known to
be G-CSF responsive [1,40,41] and whose depletion during
certain cancer therapies is thought to contribute to the de-
velopment of opportunistic infection. Due to the limi-
tations of currently available G-CSF compounds, we
evaluated the preclinical potential of G-CSF/anti-G-CSF
mAb complexes during myelosuppresion. We found that
G-CSF/anti-G-CSF mAb complexes facilitated the
rapid recovery of CD11b+Gr-1+ myeloid cells during
sublethal irradiation, cyclophosphamide treatment, or
bone marrow transplantation (Figure 4 & Additional
file 1: Figure S9). Furthermore, pretreatment with G-
CSF/anti-G-CSF mAb complexes bestowed significantly
greater protection against bacterial infection than pretreat-
ment with G-CSF alone (Figure 2). Finally, effective CD8+
T cell immune responses were not compromised following
administration of G-CSF/anti-G-CSF mAb complexes,
even during cyclophosphamide-induced myelosuppression
(Figure 3 & 5).
Perhaps the most important finding in our study was
the ability of G-CSF/anti-G-CSF mAb complexes to act
more potently in vivo than pegylated G-CSF (Figure 1D).
Our study represents the first comparison of antibody
complex technology with pegylation. While pegylation is
used to increase the activity of a number of FDA-
approved protein therapeutics, antibody cytokine tech-
nology has not yet been translated to clinical use. Our
findings suggest that antibody cytokine complex tech-
nology will be useful for improving the biological activity
for a range of protein therapeutics. In this regard it is
relevant to note that antibody cytokine complexes might
also be a particularly useful technology for patients with
anti-PEG antibodies [25-29].
Based on current indications for G-CSF-related drugs,
we envision multiple clinical applications for G-CSF/anti-
G-CSF mAb complexes. Foremost, these cytokine com-
plexes might provide an improved method for facilitating
myeloid cell recovery during cancer therapy or other mye-
losuppressive disorders, and thus, reduce the incidence of
opportunistic infections. Administration of G-CSF/anti-G-
CSF mAb complexes may also allow the administration of
higher doses of neutropenia-inducing anti-tumor therap-
ies. Another application of G-CSF/anti-G-CSF complexes
could be in the improved mobilization of progenitor cells
in the peripheral blood. This latter possibility needs fur-
ther investigation as prolonged and increased biological
activity of G-CSF may not be desirable in healthy individ-
uals or could alter the expected distribution of progenitor
cells in the blood.
In addition to enhancing the efficacy of G-CSF for
existing conditions, the increased potency of G-CSF/anti-
G-CSF mAb complexes versus existing G-CSF-based drugs
may offer other advantages. For example, the maximalpotential expansion of CD11b+Gr-1+ myeloid cells might
be greater with G-CSF/anti-G-CSF mAb complexes than
with currently available G-CSF-based drugs. This may
suggest alternate applications for G-CSF/anti-G-CSF mAb
complexes not necessarily evident from previous studies
with G-CSF. For example, burn patients or others at high
risk for infection might benefit by administration of G-
CSF/anti-G-CSF mAb complexes. Consistent with this
possibility, we found enhanced protection against bacterial
infection with antibody cytokine complexes (Figure 2) and
elevated frequencies of myeloid cells 1–3 days longer than
with G-CSF alone or PEG-G-CSF alone (Figure 1D).
The precise mechanism of how G-CSF/anti-G-CSF
mAb complexes and other cytokine complexes mediate
improved activity versus free cytokine is not known.
However, in the case of many cytokines complexes, an
increase in cytokine half-life in vivo has been observed
[32]. Thus, it is likely that binding of anti-G-CSF mAb
to G-CSF improves the half-life of G-CSF, and thus, ac-
counts for part of the enhanced biological activity. How-
ever, other mechanisms could be relevant including the
ability of antibody binding to protect the cytokine from
degradation or to impact cytokine localization. It is not-
able that free G-CSF appeared to yield relatively im-
proved responses in the bone marrow versus other
locations. This could be a consequence of the locali-
zation of Fc-expressing cells or that G-CSF-matured
neutrophils are migrating out of the bone marrow.
These and other possibilities represent important areas
for future research.
It is worth noting that while G-CSF/anti-G-CSF mAb
complexes may prove useful clinically, this technology
may act synergistically with other therapeutic strategies.
Thus, for example, as pegylation likely acts in distinct
mechanisms, our results suggest that combining pegyl-
ated G-CSF with anti-G-CSF mAb could lead to syner-
gistic improvements in biological activity. Our findings
also suggest that combining administration of G-CSF
with agents such as IL-15 that promote lymphoid cell
expansion might also be advantageous. All of these pos-
sibilities may allow for the administration of more effect-
ive regimens of cytotoxic anti-cancer therapies.Conclusion
Our results demonstrate a novel and improved method
for increasing the biological activity of G-CSF. In
addition to showing superior activity than pegylated G-
CSF, G-CSF/anti-G-CSF mAb complexes may be advanta-
geous for patients with anti-PEG antibodies. Our results
also suggest that the use of antibody cytokine complexes
methodology may be useful for increasing the biological
activity of other cytokines, such as GM-CSF, currently
used to facilitate hematopoietic recovery.
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Generation of cytokine complexes
Human (h) G-CSF (Neupogen) and PEG-G-CSF
(Neulasta) were purchased from the UCSD pharmacy (La
Jolla, CA). Anti-hG-CSF mAb (clone BVD11-37G10) was
purchased from SouthernBiotech (Birmingham, AL).
Cytokine complexes were generated by incubation of the
cytokine and antibody for 20 minutes at 37°C and diluted
at least 10-fold in phosphate-buffered saline before injec-
tion (i.p. or i.v.). G-CSF/anti-G-CSF mAb complexes were
generated at a 1:5 ratio of cytokine to antibody (1 μg of
cytokine pre-associated with 5 μg of antibody), a ratio that
ensures all cytokine is pre-bound with antibody.
Mice and in vivo protocols
C57BL/6 (B6), B6.Ly5.1 (CD45.1), RAG1−/−, OT-I, and
pmel-1 mice were purchased from the Jackson Labora-
tory (Bar Harbor, ME). All animal work was performed
under institutional and federal guidelines outlined by the
University of California, San Diego and the Medical Uni-
versity of South Carolina. Bacterial protection and the
determination of colony forming units were performed
using Listeria monocytogenes expressing ovalbumin
(LM-OVA) as previously described [54]. For experiments
using cells from OT-I TCR transgenic mice, 105 or 106
naive OT-I CD8+ T cells were injected i.v. one day before
antigenic challenge. For infections, mice were injected i.v.
with 105 plaque forming units of vesicular stomatitis virus
expressing ovalbumin (VSV-OVA) [55]. For peptide
immunization, mice were injected i.v. on day 0 with 50 μg
of SIINFEKL (OVAp) peptide (American Peptide Com-
pany, Sunnyvale, CA). Where indicated, on days 0 and 1
mice received injections i.p. with 100 μg of Poly I:C
(InvivoGen, San Diego, CA). For experiments using cells
from pmel-1 TCR transgenic mice, immunizations were
performed as we have previously described [53]. Briefly,
106 naïve pmel-1 CD8+ T cells were injected i.v. one day
after treatment with 4 mg of cyclophosphamide (Sigma,
St. Louis, MO). One and ten days after pmel-1 transfer,
mice were immunized s.c. with 100 μg of EGSRNQDWL
(gp10025-33) peptide (American Peptide) and 200 μg of
poly I:C. For bone marrow transplantation experiments,
mice were lethally irradiated (1400 rad) and adoptively
transferred with 2x106 T- and B-depleted CD45.1
congenic bone marrow cells as previously described [56].
For measurement of proliferation with Bromodeoxyuri-
dine (BrdU; Sigma), mice were injected i.v. with BrdU
(2 mg) and maintained on BrdU drinking water
(0.8 mg/ml) as previously described [57].
Flow cytometric analysis
Cells were analyzed by flow cytometry using standard tech-
niques. Briefly, cells were washed in staining buffer (PBS,
2% bovine growth serum and 0.01% sodium azide) andstained with fluorescently labeled antibodies as indicated.
The antibodies used in these studies were as follows: B220-
FITC and- PerCP (RA3-6B2; eBioscience, San Diego, CA),
CD3-PE-Cy5 (145-2C11, eBioscience); CD4-FITC (RM4-5,
eBioscience), CD8-FITC and –PerCP (53–6.7; BD Biosci-
ences PharMingen, San Diego, CA), CD11b-PE and –
Pe-Cy5 (M1/70; eBioscience), CD11c-PE and –APC
(N418, eBioscience),CD25-FITC and phycoerythrin (PE;
PC61.5; eBioscience), CD44-allophycocyanin (APC;
IM7; eBioscience), CD122-PE (TM-β1, eBioscience),
CD45.1-FITC, -PE, and –APC (A20, eBioscience),
CD45.2-FITC and –APC (104; eBioscience),CD49b-PE
and -APC (DX5; eBioscience); c-kit-PE (2B8, BD Biosci-
ences), Gr-1-FITC and PE-Cy5 (RB6-85C; eBioscience),
Ly6C- PE (HK1.4, eBioscience), Ly6G-biotin (1A8,
Biolegend), NK1.1-PE (PK136; eBioscience), Sca-1-FITC
(D7, eBioscience), and TER-119-PE-Cy5.5 (TER-119;
eBioscience). Staining for intracellular bromodeoxy-
uridine (BrdU) was performed with reagents and
according to the instructions outlined in the FITC BrdU
flow kit (559519, BD Biosciences). Flow cytometry was
performed with a BD FACS Caliber and BD Accuri (BD
Biosciences). Data were analyzed using FlowJo software
(TreeStar, San Carlos, CA).
Statistical methods
The Wilcoxon Rank-Sum test (the non-parametric alter-
native to the two-sample t-test for non-normal data) was
used to determine the statistically significant difference
between the underlying distributions of two groups. For
measurements taken over time we fitted a linear mixed
model with a log-transformed outcome and the follow-
ing effects: study group (treatment), time, and group-
time interaction. Three variance-covariance structures
were tested. The covariance that resulted in the smallest
Akaike’s information criterion was used. In all cases it
was the compound symmetry structure. If the overall
group-time interaction showed to be significant, we fur-
ther explored the differences in the levels of that inter-
action. We performed comparisons of the group levels
within each timepoint. All the analyses were carried out
using SAS 9.2 and R 3.0.1 software. Throughout the
paper all P-values presented are two-sided with 0.05 or
less considered significant.
Additional file
Additional file 1: Figure S1. G-CSF/anti-G-CSF mAb complexes induce
the expansion of CD11b+Gr-1+ myeloid cells. Figure S2. Administration
of G-CSF/anti-G-CSF mAb complexes induces CD11b+Gr-1+ myeloid cells
with a Ly6G+Ly6Clow phenotype. Figure S3. Pre-association of anti-G-CSF
mAb with pegylated G-CSF improves biological activity. Figure S4.
Long-term administration of G-CSF/anti-G-CSF mAb complexes induces
splenomegaly and dramatic expansion of CD11b+Gr-1+ myeloid cells.
Figure S5. Administration of G-CSF/anti-G-CSF mAb complexes induces
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peripheral blood. Figure S6. Extended administration of G-CSF/anti-G-
CSF mAb complexes does not affect hematocrit. Figure S7. G-CSF/anti-
G-CSF mAb complexes induce the proliferation of CD11b+Gr-1+ myeloid
cells. Figure S8. Activated CD8+ T cells proliferate normally when mixed
with splenocytes from G-CSF/anti-G-CSF mAb complex-treated mice.
Figure S9. G-CSF/anti-G-CSF mAb complexes expand CD11b+Gr-1+
myeloid cells after bone marrow transplantation. Figure S10. The
combination of G-CSF/anti-G-CSF mAb complexes and IL-15/sIL-15Rα-Fc
complexes induces more effective hematopoietic recovery following
bone marrow transplantation.
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